Renata Ltd has received approval for its inaugural filing in the Australian pharmaceuticals market. The company will introduce its contraceptive pill Levonorgestrel 1.5mg, marketed as Novella-1. Renata has registered three products for the Australian market, with approval for one and two pending. They plan to register four more drugs, aiming for a yearly export of $4-5 million within two or three years.
The contraceptive pill will be distributed through Nova Pharmaceuticals Australasia Pty Ltd, Renata’s partner with 18 years of experience supplying medicinal products to Australian pharmacies and supermarkets. Renata expressed confidence in Nova’s market presence and expects Novella-1 to reach a broad audience. The product originates from Renata’s state-of-the-art facility approved by the Therapeutic Goods Administration, reflecting the company’s commitment to quality. Renata’s stock was traded at Tk 1,217 at the Dhaka Stock Exchange.
Source for more details:
